HIMS
$24.94+0.06 (+0.24%)
Hims & Hers Health, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and int...
Recent News
Novo Nordisk (NVO) Partners With Hims & Hers, Here’s What You Need to Know
Novo Nordisk A/S (NYSE:NVO) is one of the Most Undervalued Long Term Stocks to Buy According to Analysts. On March 9, Novo Nordisk A/S (NYSE:NVO) announced its partnership with Hims & Hers. The deal entails access to Novo’s GLP-1 drugs, Ozempic and Wegovy, at Hims & Hers’ platform. ​Management noted that as part of this […]
Hims And Hers Health Pushes Into Complex Care And Global Growth
Hims & Hers Health (NYSE:HIMS) is expanding into complex health categories such as cancer care, longevity treatments, and at-home lab testing. The company is pursuing these areas through acquisitions that aim to bring more of the care journey onto its own platform. Hims & Hers Health is also ramping up international expansion, moving beyond its core US telehealth base. The shift marks a move away from a primary focus on telehealth visits and weight loss drugs toward a broader digital health...
HIMS Expands Personalized Digital Healthcare Access and Services
Hims & Hers expands its digital care platform with labs tracking, multi-cancer screening access and broader treatments as it scales personalized healthcare globally.
Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks
The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending.
Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now?
Is HIMS a good stock to buy? We came across a bullish thesis on Hims & Hers Health, Inc. on TopSecretStocks’s Substack by Simon. In this article, we will summarize the bulls’ thesis on HIMS. Hims & Hers Health, Inc.’s share was trading at $15.88 as of March 5th. HIMS’s trailing and forward P/E were 32.25 and 34.97 […]